MGNX News and Press, MacroGenics Inc. From 02/06/21

We'll take a look at an interesting therapeutic idea involving T-cells and how it's going. For some years now, Amgen has been working on a technology called "BiTE", which stands for "bispecific T-cell engager". It fits into the general "bifunctional molecule" idea that's so popular th...

Shares of MacroGenics (NASDAQ: MGNX) had jumped 5.3% as of 3:09 p.m. EST on Monday. The gain came after the company announced results from a late-stage study of Margenza as a third-line treatment for metastatic HER2-positive breast cancer. These results were published in the Journ...

MacroGenics (MGNX) announces positive data from its pivotal Phase 3 clinical trial SOPHIA testing its treatment MARGENZA (margetuximab-cmkb) in certain patients with breast cancer, in the Journal of the American Medical Association ((JAMA)) Oncology.The tria...

Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb) showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® ( trastuzumab), both with chemotherapy In the U.S., MARGENZA is approved, in combination with che...

ROCKVILLE, MD, Dec. 22, 2020 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manusc...

MacroGenics (MGNX) has entered into a research collaboration and global license agreement with Janssen Biotech (a unit of Johnson & Johnson) for the development of a preclinical bispecific molecule with Janssen Biotech.The collaboration will incorporate MacroGenics' proprietary ...

ROCKVILLE, MD, Dec. 18, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global lic...

Shares of MacroGenics (NASDAQ: MGNX) initially soared as much as 14% on Thursday but were down 3.6% as of 3:34 p.m. EST. The gyrations came after the company announced Wednesday that the U.S. Food and Drug Administration (FDA) approved Margenza in combination with chemotherapy as a ...

Takung Art (TKAT) +81%.Evolus (EOLS) +43% after company updates on U.S. ITC case related to Jeuveau sales and marketing.Skillful Craftsman Education Technology (EDTK) +17%.Marathon Patent Group (MARA) +23%.Rite Aid Corporation (RAD) +21% on Q3 results.Vivos Therapeuti...

MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® ( trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial MARGENZA is approved, in combination with che...